S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:PRQR

ProQR Therapeutics SEC Filings & 10K Form

$5.27
+0.20 (+3.94%)
(As of 01/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.70
$5.42
50-Day Range
$5.07
$8.39
52-Week Range
$4.13
$9.46
Volume
1.11 million shs
Average Volume
551,348 shs
Market Capitalization
$264.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.39

ProQR Therapeutics (NASDAQ:PRQR) SEC Filings

DateFilerForm TypeView
09/10/2021
12:03 PM
ELI LILLY & Co (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G
09/09/2021
7:01 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/05/2021
7:31 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2021
3:31 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2021
6:16 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/04/2021
6:26 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2021
6:47 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/06/2021
3:05 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2021
4:21 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/01/2021
4:17 PM
ProQR Therapeutics (Filer)
Form 424B5
04/01/2021
4:14 PM
ProQR Therapeutics (Filer)
Form 424B5
03/24/2021
7:31 AM
ProQR Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/24/2021
7:00 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/24/2021
6:00 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2021
11:47 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/12/2021
12:02 PM
GOLDMAN SACHS & CO. LLC (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/12/2021
8:32 AM
ProQR Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G/A
02/11/2021
6:51 AM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/10/2021
2:12 PM
JENNISON ASSOCIATES LLC (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/09/2021
4:00 PM
ProQR Therapeutics (Subject)
Stichting Aescap 2.0 (Filed by)
Form SC 13G/A
02/09/2021
12:02 PM
ProQR Therapeutics (Subject)
PRUDENTIAL FINANCIAL INC (Filed by)
PRUDENTIAL FINANCIAL INC (Filed by)
Form SC 13G/A
02/03/2021
12:22 PM
ProQR Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/07/2021
7:22 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/16/2020
6:00 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/05/2020
6:34 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/22/2020
3:09 PM
ProQR Therapeutics (Filer)
Form 424B5
09/21/2020
2:26 PM
ProQR Therapeutics (Filer)
Form EFFECT
09/11/2020
3:04 PM
ProQR Therapeutics (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
07/14/2020
4:21 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2020
3:10 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2020
6:31 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/31/2020
4:06 PM
ProQR Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/31/2020
3:49 PM
ProQR Therapeutics (Filer)
Form 424B5
03/31/2020
6:11 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/26/2020
6:52 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/14/2020
12:47 PM
ProQR Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G/A
02/12/2020
3:11 PM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/11/2020
6:00 AM
ProQR Therapeutics (Subject)
UBS Group AG (Filed by)
Form SC 13G/A
02/03/2020
8:45 AM
ProQR Therapeutics (Subject)
PRUDENTIAL FINANCIAL INC (Filed by)
PRUDENTIAL FINANCIAL INC (Filed by)
Form SC 13G/A
01/30/2020
8:12 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/29/2020
2:31 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
01/28/2020
10:34 AM
ProQR Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/27/2020
4:21 PM
Inspirational Visions B.V. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
12/11/2019
7:46 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/21/2019
3:09 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/08/2019
8:00 AM
ProQR Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G
10/17/2019
3:26 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/17/2019
3:22 PM
ProQR Therapeutics (Filer)
Form 424B5
10/16/2019
5:11 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/16/2019
5:08 AM
ProQR Therapeutics (Filer)
Form 424B5
10/10/2019
7:05 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2019
3:30 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/28/2019
3:30 PM
Inspirational Visions B.V. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G
08/12/2019
3:04 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/07/2019
6:55 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/29/2019
3:03 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2019
3:03 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2019
3:13 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2019
11:08 AM
ProQR Therapeutics (Filer)
Form CT ORDER
04/15/2019
6:56 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/28/2019
8:24 AM
ProQR Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/26/2019
3:11 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/11/2019
4:02 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2019
7:27 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/22/2019
2:34 PM
ProQR Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G
02/15/2019
12:05 PM
ProQR Therapeutics (Subject)
UBS Group AG (Filed by)
Form SC 13G
02/14/2019
10:37 AM
ProQR Therapeutics (Subject)
Sofinnova Partners SAS (Filed by)
Form SC 13G/A
02/14/2019
8:32 AM
ProQR Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G/A
02/13/2019
12:41 PM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/12/2019
3:16 PM
Invus Public Equities, L.P. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
02/07/2019
4:10 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G
02/01/2019
1:27 PM
JENNISON ASSOCIATES LLC (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
01/31/2019
3:08 PM
ProQR Therapeutics (Subject)
Form SC 13G/A
01/29/2019
3:31 PM
ProQR Therapeutics (Filer)
Form 6-K/A
01/29/2019
7:47 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/18/2019
3:12 PM
Inspirational Visions B.V. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G/A
01/07/2019
6:05 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/13/2018
6:30 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/10/2018
3:18 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/04/2018
7:38 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2018
11:15 PM
ProQR Therapeutics (Filer)
Form EFFECT
11/07/2018
3:55 PM
ProQR Therapeutics (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
11/07/2018
3:40 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2018
3:30 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/17/2018
3:37 PM
ProQR Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G
09/07/2018
4:15 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/07/2018
4:11 PM
ProQR Therapeutics (Filer)
Form 424B5
09/05/2018
4:02 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2018
3:57 PM
ProQR Therapeutics (Filer)
Form 424B5
09/05/2018
7:14 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/08/2018
3:37 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2018
7:10 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2018
4:00 PM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/25/2018
3:27 PM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G
05/10/2018
5:55 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2018
6:33 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/12/2018
4:29 PM
Aescap Medical Investments B.V. (Filed by)
ProQR Therapeutics (Subject)
Form SC 13G
04/11/2018
10:02 AM
ProQR Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/09/2018
1:56 PM
ProQR Therapeutics (Filer)
Form CT ORDER
03/30/2018
7:03 AM
ProQR Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.